StreetAlpha.app
Home › Stocks › CAI

Caris Life Sciences, Inc. (CAI)

Healthcare
$17.58
▼ −5.18%
LAST CLOSE · NOV 20

Caris Life Sciences provides cancer molecular profiling tests and related data services for doctors, researchers and drug developers. It last closed at $17.58 on Nov 20, down 5.18% on the day. The next earnings report for CAI is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, CAI reported EPS of $0.05 on revenue of $275.4M, with revenue up 27.0% from a year ago. Over its last 7 reports the stock moved an average of 14.0% the session after earnings. Over the last 12 months CAI insiders bought $1.5M of stock on the open market and sold $28.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is CAI in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CAI.

Key Stats

Last 12 months
Results
Revenue
$1.0B
+61.5% vs a year ago
Net income
$96.1M
9.2% margin
EPS (diluted)
$1.66
Free cash flow
$28.9M
2.8% margin
Valuation
Market cap
$5.0B
286.8M shares
P/E
10.6
Price over 12 month EPS
Price to sales
4.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Debt
$393.0M
At Sep 30
Shareholder equity
$639.5M
Buybacks
$31.5M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $306.1M$306.1MFY2023FY2024: $412.3M$412.3MFY2024FY2025: $812.0M$812.0MFY2025

From CAI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
$0.05
Quarter ended Sep 2026
Year ago EPS
$0.08
−37.5% on a GAAP basis
Revenue
$275.4M
+27.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.74Dec '24Mar 2025: -$3.57Mar '25Jun 2025: -$7.97Jun '25Sep 2025: $0.08Sep '25Dec 2025: $1.61Dec '25Mar 2026: $0.00Mar '26Jun 2026: $0.00Jun '26Sep 2026: $0.05Sep '26Latest $0.05
Revenue by quarter
Dec 2024: $129.9MDec '24Mar 2025: $120.9MMar '25Jun 2025: $181.4MJun '25Sep 2025: $216.8MSep '25Dec 2025: $292.9MDec '25Mar 2026: $216.2MMar '26Jun 2026: $263.7MJun '26Sep 2026: $275.4MSep '26Latest $275.4M
How CAI moved after its last 7 reports
Average move the session after a report ±14.0%
Nov 4, 2026After the close−21.6%
Aug 5, 2026After the close+21.6%
May 7, 2026After the close−18.6%
Feb 26, 2026After the close+4.7%
Jan 12, 2026Time not announced−10.2%
Nov 5, 2025After the close−15.8%
Aug 12, 2025After the close+5.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CAIStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CAI
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CAI

Technical Analysis

CAI · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, oversold

The stock is 53% below its 20 day and 64% below its 50 day average. It is 23% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 22), oversold. The nearest support is the swing low (Jun 30) at $17.50, and the nearest resistance the Pivot at $17.76.

Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 11.7%/day
Key levels
$36.5052 week high+107.6%
$28.8750 day average+64.2%
$26.9820 day average+53.5%
$24.66100 day average+40.3%
$21.55200 day average+22.6%
$18.24Pivot R1+3.8%
$17.84Swing high (Jun 4)+1.5%
$17.76Pivot+1.0%
$17.58Last close
$17.50Swing low (Jun 30)−0.5%
$17.09Pivot S1−2.8%
$14.1952 week low−19.3%
Indicators
RSI (14)21.75Oversold below 30Oversold
MACD-3.13Below its signal lineBearish
Stochastic1.1Near the bottom of its rangeOversold
ADX (14)42.4Strong downtrend
Williams %R-98.2Oversold below −80, overbought above −20Oversold
CCI (20)-117.5Oversold below −100, overbought above 100Oversold
Rate of change−30.3%Change over 10 sessionsBearish
ATR (14)$2.05Typical daily range, 11.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CAI

What happened before

See how CAI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for CAIHow many large options trades hit CAI, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

CAI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲232 buying vs 107 selling
  • ●Held by funds +0.4 pts
  • ▲Funds holding +81
  • ▼Superinvestors: 2 added, 3 cut
  • ●Put/call not meaningful
Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding330249+32.5%
In funds' top 1056−16.7%
Held by funds54.2%53.8%+0.4 pts
New / increased122 / 11068 / 105+34.1%
Reduced / sold out67 / 4048 / 24+48.6%
Put/call ratio0.250.64−60.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CAI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CAI Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$1.5M2 buys · 2 insiders
Sold$28.9M4 sales · 4 insiders
6% of the selling was under pre-arranged trading plans.
Cluster buy: 2 insiders bought $1.5M between May 11 and May 15.
2025-12 sold $1.7M2026-05 bought $1.5M2026-09 sold $27.2MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 22John Russel DentonSee RemarksSale7,500$31.82$239K
Sep 17Brian J BrilleSee RemarksSale400,000$30.33$12.1M
Sep 4David Baxley SpetzlerPresidentSale597,212$24.84$14.8M
May 15Jon HalbertDirectorBuy68,000$14.56$990K
May 11Jeff L VacircaDirectorBuy31,050$16.15$501K
Dec 11, 2025Luke Thomas PowerSee RemarksSale plan62,250$26.57$1.7M
Every insider buy and sale for CAI over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CAI insider trades →

From SEC Form 4 filings by CAI's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CAI is in one of them and how their past CAI trades turned out.

CAI in the AI portfolios
Loading…

CAI News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CAI in an article yet. Here's the latest on the wider market.

CAI in the news

About Caris Life Sciences

Caris Life Sciences, based in Irving, Texas, offers molecular profiling tests that analyze tumor tissue and blood samples to help guide cancer care. Its tests combine gene sequencing with artificial intelligence analysis, and it also sells data and bioinformatics services. Its customers include physicians and clinical labs, academic cancer research centers, and biopharma companies developing new drugs. The company focuses mainly on oncology.

Headquarters
Irving, TX